Last reviewed · How we verify
NCT03995030
Massively Parallel Sequencing to Identify Microbiological Organisms in Bronchoalveolar Lavage Fluid
trial testing massively paralleled sequencing in Pulmonary Infection in 10 participants. Completed in 31 December 2021.
31 January 2019
Quick facts
| Lead sponsor | New York Medical College |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 10 |
| Start date | 15 September 2016 |
| Primary completion | 31 January 2019 |
| Estimated completion | 31 December 2021 |
Drugs / interventions tested
- massively paralleled sequencing
Conditions studied
- Pulmonary Infection — all drugs for Pulmonary Infection →
Sponsor
New York Medical College
Who can join
Adults 0 to 29, any sex, with Pulmonary Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients who are post hematopoietic stem cell transplantation who require a bronchoalveolar lavage (BAL) for standard clinical car will have extra fluid collected and sent for massively parallel sequencing to see if it is as sensitive for detecting a microbial pulmonary infection compared to standard cultures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03995030
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Infection
Currently open trials in the same condition.
- NCT07389083 — The Efficacy and Safety of the Supraglottic Oxygenation Via Nasotracheal Intubation for Deep Sedation Fiberoptic Broncho · NA · recruiting
- NCT06319274 — Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure · Phase 2 · recruiting
- NCT05505487 — Construction and Effect Evaluation of Integrated Care Model for Pulmonary Infection in Stroke Patients With Tracheotomy · NA · recruiting
- NCT04624490 — Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease · Phase 1 · recruiting
Other New York Medical College trials
Trials by the same sponsor.
- NCT06617286 — CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma · Phase 1, PHASE2 · not yet recruiting
- NCT07225972 — Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC · Phase 3 · not yet recruiting
- NCT07013565 — Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL · Phase 2 · active not recruiting
- NCT05987124 — Defibrotide Dose-escalation for SOS Post-HSCT · Phase 2 · recruiting
- NCT05564598 — CMV CTLs in Neonates With CMV Infection · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03995030 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York Medical College
- Last refreshed: 25 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03995030.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing